QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
Log in
NASDAQ:TLMD

SOC Telemed Competitors

$6.94
-0.55 (-7.34 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.35
Now: $6.94
$7.49
50-Day Range
$6.81
MA: $7.82
$9.00
52-Week Range
$6.35
Now: $6.94
$12.08
Volume1.26 million shs
Average Volume496,770 shs
Market Capitalization$621.99 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

SOC Telemed (NASDAQ:TLMD) Vs. FMS, DVA, SHC, PGNY, TVTY, and OTRK

Should you be buying TLMD stock or one of its competitors? Companies in the industry of "miscellaneous health & allied services, not elsewhere classified" are considered alternatives and competitors to SOC Telemed, including Fresenius Medical Care AG & Co. KGaA (FMS), DaVita (DVA), Sotera Health (SHC), Progyny (PGNY), Tivity Health (TVTY), and Ontrak (OTRK).

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) and SOC Telemed (NASDAQ:TLMD) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Profitability

This table compares Fresenius Medical Care AG & Co. KGaA and SOC Telemed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fresenius Medical Care AG & Co. KGaA7.38%10.62%4.15%
SOC TelemedN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Fresenius Medical Care AG & Co. KGaA and SOC Telemed, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fresenius Medical Care AG & Co. KGaA19702.35
SOC Telemed01502.83

Fresenius Medical Care AG & Co. KGaA presently has a consensus target price of $45.00, indicating a potential upside of 30.93%. SOC Telemed has a consensus target price of $11.40, indicating a potential upside of 64.27%. Given SOC Telemed's stronger consensus rating and higher possible upside, analysts plainly believe SOC Telemed is more favorable than Fresenius Medical Care AG & Co. KGaA.

Insider & Institutional Ownership

1.6% of Fresenius Medical Care AG & Co. KGaA shares are held by institutional investors. Comparatively, 20.7% of SOC Telemed shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Fresenius Medical Care AG & Co. KGaA and SOC Telemed's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fresenius Medical Care AG & Co. KGaA$19.58 billion1.03$1.34 billion$2.5313.58
SOC TelemedN/AN/A$20,000.00N/AN/A

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than SOC Telemed.

Summary

Fresenius Medical Care AG & Co. KGaA beats SOC Telemed on 6 of the 9 factors compared between the two stocks.

SOC Telemed (NASDAQ:TLMD) and DaVita (NYSE:DVA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Profitability

This table compares SOC Telemed and DaVita's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SOC TelemedN/AN/AN/A
DaVita7.32%43.99%5.27%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for SOC Telemed and DaVita, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SOC Telemed01502.83
DaVita04102.20

SOC Telemed currently has a consensus price target of $11.40, indicating a potential upside of 64.27%. DaVita has a consensus price target of $116.40, indicating a potential upside of 12.12%. Given SOC Telemed's stronger consensus rating and higher probable upside, analysts plainly believe SOC Telemed is more favorable than DaVita.

Insider and Institutional Ownership

20.7% of SOC Telemed shares are owned by institutional investors. Comparatively, 91.7% of DaVita shares are owned by institutional investors. 1.0% of DaVita shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares SOC Telemed and DaVita's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SOC TelemedN/AN/A$20,000.00N/AN/A
DaVita$11.39 billion1.00$810.98 million$5.4019.23

DaVita has higher revenue and earnings than SOC Telemed.

Summary

DaVita beats SOC Telemed on 7 of the 10 factors compared between the two stocks.

SOC Telemed (NASDAQ:TLMD) and Sotera Health (NYSE:SHC) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Profitability

This table compares SOC Telemed and Sotera Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SOC TelemedN/AN/AN/A
Sotera HealthN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for SOC Telemed and Sotera Health, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SOC Telemed01502.83
Sotera Health001003.00

SOC Telemed currently has a consensus price target of $11.40, indicating a potential upside of 64.27%. Sotera Health has a consensus price target of $32.55, indicating a potential upside of 27.60%. Given SOC Telemed's higher probable upside, analysts plainly believe SOC Telemed is more favorable than Sotera Health.

Insider and Institutional Ownership

20.7% of SOC Telemed shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares SOC Telemed and Sotera Health's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SOC TelemedN/AN/A$20,000.00N/AN/A
Sotera HealthN/AN/AN/AN/AN/A

SOC Telemed (NASDAQ:TLMD) and Progyny (NASDAQ:PGNY) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Profitability

This table compares SOC Telemed and Progyny's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SOC TelemedN/AN/AN/A
Progyny1.03%7.43%5.04%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for SOC Telemed and Progyny, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SOC Telemed01502.83
Progyny01502.83

SOC Telemed currently has a consensus price target of $11.40, indicating a potential upside of 64.27%. Progyny has a consensus price target of $35.8333, indicating a potential downside of 11.87%. Given SOC Telemed's higher probable upside, analysts plainly believe SOC Telemed is more favorable than Progyny.

Valuation & Earnings

This table compares SOC Telemed and Progyny's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SOC TelemedN/AN/A$20,000.00N/AN/A
Progyny$229.68 million15.34$-8,570,000.00$0.11369.64

SOC Telemed has higher earnings, but lower revenue than Progyny.

Insider and Institutional Ownership

20.7% of SOC Telemed shares are owned by institutional investors. Comparatively, 58.5% of Progyny shares are owned by institutional investors. 33.3% of Progyny shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Progyny beats SOC Telemed on 6 of the 8 factors compared between the two stocks.

SOC Telemed (NASDAQ:TLMD) and Tivity Health (NASDAQ:TVTY) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Profitability

This table compares SOC Telemed and Tivity Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SOC TelemedN/AN/AN/A
Tivity Health-47.44%128.43%6.11%

Analyst Ratings

This is a breakdown of recent ratings and target prices for SOC Telemed and Tivity Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SOC Telemed01502.83
Tivity Health12502.50

SOC Telemed currently has a consensus price target of $11.40, indicating a potential upside of 64.27%. Tivity Health has a consensus price target of $22.1250, indicating a potential downside of 5.21%. Given SOC Telemed's stronger consensus rating and higher probable upside, equities research analysts plainly believe SOC Telemed is more favorable than Tivity Health.

Valuation and Earnings

This table compares SOC Telemed and Tivity Health's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SOC TelemedN/AN/A$20,000.00N/AN/A
Tivity Health$1.13 billion1.00$-286,820,000.00$2.0211.55

SOC Telemed has higher earnings, but lower revenue than Tivity Health.

Insider & Institutional Ownership

20.7% of SOC Telemed shares are owned by institutional investors. Comparatively, 91.6% of Tivity Health shares are owned by institutional investors. 11.8% of Tivity Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Tivity Health beats SOC Telemed on 5 of the 9 factors compared between the two stocks.

SOC Telemed (NASDAQ:TLMD) and Ontrak (NASDAQ:OTRK) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Profitability

This table compares SOC Telemed and Ontrak's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SOC TelemedN/AN/AN/A
Ontrak-43.10%N/A-58.54%

Analyst Ratings

This is a breakdown of recent ratings and target prices for SOC Telemed and Ontrak, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SOC Telemed01502.83
Ontrak03202.40

SOC Telemed currently has a consensus price target of $11.40, indicating a potential upside of 64.27%. Ontrak has a consensus price target of $54.00, indicating a potential upside of 121.40%. Given Ontrak's higher probable upside, analysts plainly believe Ontrak is more favorable than SOC Telemed.

Valuation and Earnings

This table compares SOC Telemed and Ontrak's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SOC TelemedN/AN/A$20,000.00N/AN/A
Ontrak$35.10 million12.10$-25,660,000.00($1.15)-21.21

SOC Telemed has higher earnings, but lower revenue than Ontrak.

Insider & Institutional Ownership

20.7% of SOC Telemed shares are owned by institutional investors. Comparatively, 27.5% of Ontrak shares are owned by institutional investors. 58.2% of Ontrak shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

SOC Telemed beats Ontrak on 5 of the 9 factors compared between the two stocks.


SOC Telemed Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Fresenius Medical Care AG & Co. KGaA logo
FMS
Fresenius Medical Care AG & Co. KGaA
1.9$34.37-1.0%$20.13 billion$19.58 billion13.64Analyst Report
Increase in Short Interest
DaVita logo
DVA
DaVita
2.0$103.82-1.0%$11.36 billion$11.39 billion15.57
Sotera Health logo
SHC
Sotera Health
2.3$25.51-3.4%$7.08 billionN/A0.00Upcoming Earnings
Analyst Report
Progyny logo
PGNY
Progyny
1.5$40.66-5.2%$3.52 billion$229.68 million369.64
Tivity Health logo
TVTY
Tivity Health
1.0$23.34-1.3%$1.13 billion$1.13 billion-2.11Analyst Upgrade
Analyst Revision
Ontrak logo
OTRK
Ontrak
1.5$24.39-6.7%$424.78 million$35.10 million-14.35Analyst Downgrade
High Trading Volume
Unusual Options Activity
News Coverage
VMD
Viemed Healthcare
1.1$9.70-7.4%$380.09 million$80.26 million13.47High Trading Volume
Baudax Bio logo
BXRX
Baudax Bio
1.4$1.20-8.4%$83.82 millionN/A-0.34
GRNV
GreenVision Acquisition
0.3$10.17-0.1%$73.10 millionN/A0.00Increase in Short Interest
Caladrius Biosciences logo
CLBS
Caladrius Biosciences
1.5$1.82-4.4%$60.00 millionN/A-2.84Earnings Announcement
Analyst Upgrade
Unusual Options Activity
News Coverage
This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.